Vanda Pharmaceuticals' Hetlioz approved in Europe for sleep disorder

8 July 2015

The European Commission has announced that Hetlioz (tasimelteon) from US pharma company Vanda Pharmaceuticals (Nasdaq: VNDA) has been approved to treat non-24-hour sleep-wake disorder in totally blind adults.

This marketing authorization allows for the marketing of Hetlioz in all 28 European Union member states as well as European Economic Area members Iceland, Liechtenstein and Norway. It has also confirmed orphan drug designation for Hetlioz in the treatment of the disorder in totally blind adults.

Mihael Polymeropoulous, president and chief executive of Vanda, said: "The European approval of Hetlioz is an important milestone for the Non-24 patients throughout the European Union who live with this debilitating disorder.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK